HYDRATED CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
CANNON, HILARY,肯诺 西勒瑞,肯諾 西勒瑞,KANG, FEIRONG,姜飞容,姜飛容,VOGT, FREDERICK G.,维格特 佛德瑞克G,維格特 佛德瑞克G
申请号：
TW100108394
公开号：
TW201202228A
申请日:
2011.03.11
申请国别(地区):
TW
年份:
2012
代理人:
摘要：
This invention relates crystalline hydrates of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Compound (I). The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline hydrate of Compound (I) and a pharmaceutically acceptable excipient.本發明係關於化合物(I)N-[3-氟-4-({6-(甲氧基)-7-[(3-嗎福林-4-基丙基)氧基]喹啉-4-基}氧基)苯基]-N-(4-氟苯基)環丙烷-1,1-二甲醯胺之結晶水合物。本發明提供藉由利用對蛋白激酶活性之調節來治療癌症之方法。本發明亦提供含有化合物(I)之結晶水合物及醫藥學上可接受之賦形劑的醫藥組合物。(無元件符號說明)
